Deregulation of the cyclin-dependent kinases 4 and 6 (CDK4/6) is highly prevalent in cancer yet inhibitors against these kinases currently show use in restricted tumour contexts. The extent to which cancers depend on CDK4/6 and what may undermine such dependency is poorly understood. Here we report that signalling engaging the MET proto-oncogene receptor tyrosine kinase/focal adhesion kinase (FAK) axis leads to CDK4/6-independent CDK2-activation, involving as a critical mechanistic events loss of the CDK inhibitor p21 CIP1 and gain of its regulator, the ubiquitin ligase subunit SKP2. Combined inhibition of MET/FAK and CDK4/6 eliminates proliferation capacity of cancer cells in culture, and enhances tumour growth inhibition in vivo. Activation of the MET/FAK axis is known to arise through cancer extrinsic and intrinsic cues. Our work predicts that such cues support cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases and identifies MET/FAK as a tractable route to broaden the utility of CDK4/6 inhibitor-based therapies in the clinic.
Introduction
The cyclin-dependent kinases CDK4 and CDK6 are core components of the signal transduction network controlling transition of cells from G1 (Gap1) phase of the cell cycle into S (DNA synthesis) [1, 2] . Deregulation of this is a common event in cancer. Multiple oncogenic pathways promote the synthesis of the activator D-type cyclins, and gene mutation of regulators involved in limiting CDK4/6-activation are exceptionally frequent in all types of cancer [3, 4] . The high frequency by which CDK4/6 control is compromised in cancer implies that CDK4/6 deregulation is a key event enabling cancer development and, by extension, that inhibition of CDK4/6 could be a broadly applicable and effective approach to cancer treatment [2, 5] .
Several potent, selective inhibitors targeting CDK4/6 (CDK4/6is) have undergone clinical trials including palbociclib (PD0332991), abemaciclib (LY-2835219) and ribociclib (LEE001) [6, 7] , and have gained regulatory approval in combination with hormonal therapy in breast cancer [8] [9] [10] [11] . However, evidence for clinical benefit has not been extended to other cancer types thus far, and relapse under therapy is frequent in the approved indication in breast cancer [9] .
Activation of CDK4/6 requires their binding to D-type cyclins, synthesised in response to mitogenic signals [12, 13] . Bound to these cyclins CDK4/6 phosphorylates the retinoblastoma tumour suppressor protein (RB1), initiating its inactivation. RB1 in its active form prevents the transcription of genes required for S phase entry including those encoding the E-and A-type cyclins, involved in the activation of the CDK4/6 related S phase cyclindependent kinase CDK2 [14] . In addition RB1 promotes the ubiquitin-dependent destruction of the SCF (SKP1-CUL1-F-box protein) E3-ubiquitin-ligase substrate-recognition subunit SKP2, stabilizing the CDK2 inhibitory proteins p21 CIP1 and p27 KIP1 , the degradation of which is SKP2-dependent [15, 16] . Together these activities limit CDK2-activation safeguarding licensed DNA synthesis and cell cycle transit.
Numerous reports describe situations where activation of CDK2 is enabled in the absence of CDK4/6 activity and that CDK2 can drive cycle transit in the absence CDK4/6 activity [17] [18] [19] [20] [21] [22] [23] [24] . Hence activation of CDK2, independent of CDK4/6 activity, may limit the potency of CDK4/6is in cancers and identification of signalling required for CDK2-activation may yield information that predicts, or could be exploited to extend their efficacy in cancer therapy.
Here we report a mechanism-focussed screen aimed at identifying signalling that enables CDK4/6-independent CDK2-activation. We identify a prominent role of the MET protooncogene tyrosine kinase receptor family and their downstream effectors, the focal adhesion kinase (FAK) family. Our data validate MET/FAK signalling as a mechanism that enables CDK4/6-independent CDK2-activation and cell cycle transit and we provide evidence for the utility of MET-inhibition as a means to improve tumour response to CDK4/6-inhibition in vivo.
Results

Screening identifies proteins required for CDK2-activation in CDK4/6-inhibited cells.
To assess CDK2-activation in cells exposed CDK4/6i), we used a cell-based CDK2 reporter (GFP-PSLD) where a green fluorescent protein (GFP) is fused to the CDK2-regulated phosphorylated subcellular localization domain (PSLD) of human DNA helicase B [25] .
Phosphorylation of the PSLD by CDK2 exposes a nuclear export sequence initiating export of the GFP fusion protein from the nucleus to the cytoplasm (Fig. 1a) . We made use of human colorectal carcinoma HCT116 cells (HCT116) that stably express the CDK2 reporter (HCT116-PSLD) [26] . Treatment of HCT116-PSLD using either siRNA targeting CDK2 or the CDK4/6i palbociclib significantly increased the fraction of cells with predominantly nuclear fluorescence (nuclear: cytoplasmic (nuc/cyto) fluorescence ratio > 1.5), consistent with reliance of reporter localization on CDK2, and CDK4/6-activation ( Supplementary Fig.   1a -c). However, although palbociclib treatment increased the percentage of cells with nuclear-localised CDK2 reporter, a considerable portion of cells with loss of CDK4/6 activity, detected by the absence of RB1 phosphorylated at the CDK4/6-selective phosphorylation site Ser780 (pRB1 S780 ) [27] , continued to contain reporter with predominant cytoplasmic localization ( Supplementary Fig. 1d , e). This indicates CDK4/6-independent CDK2-activation. Unexpectedly we observed that ablation of the tumour suppressor TP53 reduced CDK2 control by palbociclib, even though the cells remained responsive to CDK4/6-inhibition, indicated by the reduction in cells containing pRB1 S780 (Supplementary Fig. S1f and S1g).
To identify signalling that permits CDK4/6-independent CDK2 activation, we transfected HCT116-PSLD with a library of small interfering RNA (siRNA) pools targeting kinases and kinase-relevant components (Fig. 1B) and assessed the ability of palbociclib to restrain CDK2-activation under these conditions (Fig. 1b) . Since we observed relaxed CDK2 control following ablation of TP53 and because functional TP53 loss is frequent in cancer, we included an arm to the screen where we compromised TP53 expression using TP53-targeted siRNA.
To identify siRNA pools that selectively decreased CDK2 activity subject to palbociclib treatment we computed the sensitivity index (SI), which quantifies the difference between expected combined and measured observed effects of two treatments [28, 29] , in this case the effects of specific siRNAs and the effect of CDK4/6-inhibition on CDK2 activity. Ranking the SI values calculated using Z-score statistics (Fig. 1c) we selected siRNA pools with Zscores > 2 for further analysis, yielding 30 pools that selectively decreased CDK2 in combination with CDK4/6-inhibition in HCT116-PSLD, and 23 in HCT116-PSLD with compromised TP53-expression.
Most siRNA pools identified in TP53-compromised HCT116-PSLD decreased CDK2 activity also in HCT116-PSLD. Conversely, less than half identified in HCT116-PSLD decreased CDK2 activity in TP53-modified cells (Fig. 1d) . These results indicate differences in the regulation of CDK2 in TP53-normal and TP53-imparied backgrounds but at the same time outline opportunity to enhance the dependence of CDK2-activation on CDK4/6 in cells, regardless of TP53 status.
MET/FAK signalling is required for CDK2-activation in CDK4/6-inhibited cells
To mine for annotated pathways overrepresented amongst the siRNA targets identified against those screened we used the MetaCore TM GeneGO tool (Supplementary tables 1 and 2), predicting as most significantly enriched a well-connected hub involving the MET proto-oncogene/hepatocyte growth factor receptor (MET) and the closely related macrophage growth factor receptor (MSTR1/RON) along with fibroblast growth factor receptor 3 (FGFR3) and their common downstream signalling targets, the focal adhesion kinases PTK2 and PTK2B (Fig. 2a) .
Two or more distinct siRNAs targeting MET, MST1R, PTK2 or PTK2B synergistically increased the percentage cells with nuclear-localised PSLD-GFP following CDK4/6-inhibition ( Fig. 2b) validating the involvement MET and FAK family members in enabling CDK4/6-independent CDK2-activation in cells. Combined use of MET and MST1R or PTK2
and PTK2B siRNA did not enhance outcome, suggesting an independent, rate-limiting contribution of individual MET and FAK family kinases in this context. Notably, treatment with chemical inhibitors targeting either the MET or FAK family kinases synergistically decreased CDK2 activity in combination with palbociclib (Fig. 2c) . The activity of network components FGFR3, SRC and JAK did not confirm with multiple oligonucleotides (Fig. 2b) .
Hence the involvement of these components in enabling CDK4/6-independent CDK2-activation cannot be certain.
To assess if inhibition of MET enables CDK2 control by enhancing the efficacy of the inhibitor to control CDK4/6, we assessed loss of pRB1 S780 (Fig. 2d ) in HCT116-PSLD subject to individual and combined use of inhibitors. As expected we observed a significant increase in the fraction of pRB1 S780 negative cells following CDK4/6-inhibition. Conversely, MET-inhibition did not significantly increase the fraction of pRB1 S780 negative cells.
Importantly, combined inhibition of CDK4/6 and MET was no more effective at raising the fraction of pRB1 S780 negative cells than inhibition of CDK4/6 alone at any concentration tested. Nevertheless, and in agreement with our earlier results, combined inhibition of CDK4/6 and MET led to a significantly greater reduction of cells with active CDK2 than treatment with either inhibitor alone (Fig. 2e) . Chou-Talalay concentration-effect analysis [30] identified a robust synergistic interaction between MET and CDK4/6-inhibition towards reducing CDK2 activity, returning combination index (CI) values well below 1 across the concentration range tested (Fig. 2e) ⎯irrespective of TP53 status. Hence, MET-inhibition cooperates with palbociclib to control CDK2-activation but does not itself affect, or enhance, the ability of CDK4/6is to supress CDK4/6 activity.
Combined MET and CDK4/6-inhibition synergistically affects tumour cell fate in vitro
and reduces tumour growth in vivo.
Since MET-inhibition synergised with CDK4/6-inhibition to enable the control of CDK2 activity, we tested if this treatment would also synergise to enable other responses associated with CDK4/6-inhibition. Inhibition of CDK4/6 is recognised for its ability to trigger permanent cell cycle exit, thought to underlie its anticancer activity [31] . To assess if MET inhibition enhances permanent cell cycle exit subject to CDK4/6-inhibition, we exposed cells for five consecutive days to inhibitors, then quantified their ability to form colonies by seeding equal numbers of live cells into inhibitor-free medium (Fig. 3) . We initially measured the response of HCT116, using two chemically unrelated inhibitors for CDK4/6, palbociclib and abemaciclib, and chemically unrelated inhibitors of MET family kinases, crizotinib and foretinib ( Fig. 3a-d ), in accordance with best practice [32] .
Combinatorial treatment significantly enhanced the reduction in colony outgrowth compared to individual inhibitors (p < 0.01, 2-way ANOVA (Fig. 3a) . Thus, pRB1 S780 had decreased where CDK4/6is were used, while MET auto-phosphorylated on Tyr1234/1235 (pMET Y1234/5 ) had decreased in cells exposed to the METis. As noted previously MET-inhibition did not affect pRB1 Combined inhibition of MET and CDK4/6 also synergised towards loss of Ki-67 expression ( Fig. 4a-d and Supplementary Fig. 2 ). Loss of Ki-67 is indicative of cell cycle exit [34] and predicts response to CDK4/6-inhibition in preclinical models [7] . Combined inhibition of Fig. 2c ), indicating that the observed effect is robust and involves on-target MET and CDK4/6-inhibition.
Importantly, MET and CDK4/6-inhibition synergistically reduced Ki-67 expression across cancer cell lines with diverse tissues-of-origin and genetic driver profiles ( Fig. 4c and 4d ).
Concentration-effect analysis confirmed a synergistic interaction for 10 out of 12 lines tested.
Notable exceptions were two RB1-mutated lines, the osteosarcoma line SAOS2 and the cervical cancer cell line C-33A, where combination treatment had additive or less than additive effects ( Fig. 4c and 4d) , consistent with the notion that RB1 is a critical downstream effector of CDK4/6 and that RB1 loss renders cells unresponsive to CDK4/6is. Thus combined MET and CDK4/6-inhibition synergises broadly across cancer histio-and genotypes. The absence of synergism in RB1-mutated backgrounds identifies RB1 activity as a critical component required for this synergistic interaction.
We also assessed if combined inhibition of MET and CDK4/6 enhances or enables senescence by quantifying senescence-associated -galactosidase (SA−-gal) in cells.
CDK4/6is induce cellular senescence, which is thought to underlie the loss of clonogenic activity they induce [3, 31, 35] . Using C12FDG, a beta-galactosidase substrate with green- 3d ).
Finally, we evaluated cell proliferation activity using cells modified to express the nuclear marker GFP-H2B to track division by time-lapse microscopy ( Supplementary Fig. 3e-i) .
These experiments revealed a synergistic reduction in duplication activity subject to combined inhibition of MET and CDK4/6-irrespective of TP53 status.
Together these results support the notion that MET-inhibition synergistically increased known cellular responses associated with CDK4/6-inhibition. Conversely, the results support a role for MET in preventing these responses in cells treated with CDK4/6is
including responses that predict anti-tumour response to CDK4/6-inhibition in vivo.
To test if CDK4/6-inhibition combined with MET-inhibition is a feasible strategy for cancer treatment in vivo, we assessed the effect of combined use of crizotinib and palbociclib on the growth of human tumour xenografts in athymic mice. Combined use of 100 mg/ kg (p.o.)
crizotinib and palbociclib was well tolerated in the mice ( Fig. 4g ) yielding effective accumulation of agents within tumour tissue ( Fig. 4i ) and modulation of pRB1 S780 and pMET Y1234/5 pharmacodynamic biomarkers over a 24 h period (Fig. 4k ).
Using this dose we treated mice bearing HCT116 TP53 -/-tumour xenografts ( Together, these results provide evidence that MET activity constitutes a resistance mechanism in vitro and in vivo, broadly reducing the tumour cell response to CDK4/6-inhibition. Importantly, our findings indicate that combined pharmacological inhibition of MET and CDK4/6 is a feasible strategy able to improve tumour growth inhibition in mice, indicating the potential of this combination for clinical use.
Synergistic inhibition of CDK2 by MET and CDK4/6is involves p21
CIP1
To identify the mechanism by which MET and CDK4/6-inhibition synergise we characterised activity and composition of the CDK2 complex in inhibitor-treated cells using immunoprecipitation. These experiments confirmed a significant reduction in CDK2 activity subject to combined MET and CDK4/6-inhibition, determined by the ability of the anti-CDK2
immunoprecipitates to yield phosphorylation of substrate (GST-RB 763-928) in vitro ( Fig.   5a , 5b, Supplementary Fig. 4b and 4c).
The decrease in CDK2 activity was not accompanied by a decrease in the amount of Cyclin E1 (CCNE1) or a change in the phosphorylation of CDK2 at Tyr15 (pCDK2 Y15 ) or Thr160 (pCDK2 T160 ), known to confer negative and positive regulation of CDK2 activity, respectively [36] (Fig. 5a ). However, there was a significant increase in the amount of the CDK inhibitor protein p21 CIP1 in precipitates from cells treated with combined MET and CDK4/6i, as compared to single agent-or vehicle-treated cells. Decreased CDK2 activity and increased presence of p21 CIP1 in anti-CDK2 precipitates were consistently observed in multiple tumour cell lines subject to combined MET and CDK4 inhibition ( To assess if the increased association of p21 CIP1 with the CDK2 complex links to increased p21 CIP1 abundance, we analysed lysate from treated cells using immunoblotting (Fig. 5e) . A progressive increase in p21 CIP1 abundance was seen between 24 h and 48 h subject to combination treatment ( Fig. 5e and 5f ). This increase in p21 CIP1 was apparent in TP53 -/-HCT116, indicative that the upregulation of p21 CIP1 , a known target transcriptionally activated by TP53, is TP53-independent. We also examined the abundance of the two other members of the CIP/KIP CDK inhibitor family, revealing an increase in p27 KIP1 at 48 h, but not at earlier times. No change in the levels of p57 KIP2 was observed ( Fig. 5e and 5f ).
We further assessed the level of the SKP1-cullin-F-box ubiquitin ligase substrate recognition subunit (SKP2), involved in regulating the stability of CIP/KIP family proteins. A clear reduction in SKP2, detectable at 24 h and pronounced at 48 h, was seen following combined inhibition of MET and CDK4/6 compared with vehicle-treated HCT116 ( Fig. 5e and 5f). The abundance of SKP2 was not affected following CDK4/6 or MET-inhibition alone.
Combined MET and CDK4/6-inhibition leads to upregulation of p21 CIP1 and loss of SKP2 in multiple cell backgrounds ( Fig. 5g and 5h ), indicative that this response is broadly observable. Together, these experiments indicate that signalling through MET and CDK4/6 act redundantly to down-regulate the CDK inhibitors p21 CIP1 and p27 KIP1 , and to up-regulate their regulator SKP2, in turn providing a potential explanation why combined inhibition of MET and CDK4/6 is required for the inhibition of CDK2 and cellular proliferation capacity.
To evaluate if CIP/KIP family members are involved in the synergistic control of CDK2, we depleted the CDK inhibitors alone or in combination using siRNA and, using the localisation of the GFP-PSLD reporter, assessed the effect of this on CDK2 control (Fig. 5i) . These experiments positively identified p21 CIP1 as a critical mechanistic component in the control of CDK2 by combined MET-and CDK4/6-inhibition. Thus, transfection of cells with siRNA targeting CDKN1A (which encodes p21 CIP1 ) consistently prevented CDK2 control by the combination. siRNA targeting CDKN1B (encoding p27 KIP1 ) and CDKN1C (encoding p57 KIP2 ) alone or in combination had no effect, despite evidence that the siRNAs effectively depleted the proteins concerned (Fig. 5k) . Similar results were obtained in cells simultaneously transfected with TP53-targeted siRNA (Fig. 5i) , extending evidence for a critical role of p21 CIP1 , regardless of TP53 status.
CDK2 regulation by the MET-and CDK4/6i combination was also prevented following loss of RB family proteins (Fig. 5l) , consistent with the known resistance to CDK4/6is of cells with functional RB loss and indicative of a critical mechanistic role of RB protein function in the control of CDK2 by combined MET and CDK4/6-inhibition.
Constitutive FAK activity abolishes cooperation between METis and CDK4/6is.
Our siRNA screen identified the FAK family kinases PTK2 and PTK2B, which are known MET effectors, as candidates that facilitate CDK4/6 independent CDK2-activation. Hence we sought evidence if signalling through these kinases is involved in the CDK4/6-independent CDK2-activation by MET and whether additional MET-engaged signalling might play a role. MET and its close relative MST1R connect to multiple effector pathways, amongst them RAS/RAF/ERK, PIK3K/AKT, SRC and STAT3, which they activate in addition to signal transduction involving the FAK/PTK family ( Supplementary Fig. 5a ).
While effectively blocking MET auto-phosphorylation within the catalytic region (pMET To obtain evidence if FAK family-activation through MET is involved in CDK4/6i-resistant CDK2-activation, we generated HCT116 expressing a membrane-targeted, constitutively active PTK2 variant, CD2-PTK2 (Fig. 6a) . Expression of CD2-PTK2 did not affect the ability of MET-inhibition to block MET receptor activity, or the ability of CDK4/6-inhibition to block RB1 phosphorylation (Fig. 6a) . However, expression of CD2-PTK2 permitted sustained,
METi-resistant PTK2-activation, indicated by the presence of pY576/577 phosphorylated CD2-PTK2 (Fig. 6a) . Significantly, in cells expressing CD2-PTK2 the activity of CDK2 in anti-CDK2 immunoprecipitates was unaffected by combined inhibition of CDK4/6 and MET ( Fig. 6b and 6c) . Furthermore, the increased association of p21 CIP1 following combined CDK4/6 and MET-inhibition was abolished ( Fig. 6b and 6d and Supplementary Fig. 5c -5f ).
Notably, expression of CD2-FAK reduced the ability of combined CDK4/6 and METinhibition to decrease colony formation in HCT116 ( Fig. 6e and 6e) , irrespective of TP53 status. It also reduced the increase in p21 CIP1 and the loss of SKP2, associated with combined MET and CDK4/6-inhibition ( Fig. 6g and 6h ). Together these results indicate that reduction of FAK activity is key to limiting CDK2 and clonogenic activity following from combined MET and CDK4/6-inhibition in cells.
The finding that combined inhibition of the MET/FAK and CDK4/6 axis can promote p21 CIP1 accumulation in HCT116 TP53 -/-implies a mechanism for TP53-independent generation of p21 CIP1 , conferred by inhibition of the MET/FAK axis. Consistent with this, and regardless of TP53 status, we observed a significant increase in CDKN1A mRNA (encoding p21 CIP1 )
following combined CDK4/6 and MET-inhibition compared to control or CDK4/6i treated cells, (Fig. 6i) , which was abolished by the expression of constitutively active PTK2. Notably, the level of CDKN1A mRNA increased in cells treated with METi alone, indicating that CDKN1A transcription is suppressed by signalling through MET/FAK, independent of CDK4/6. Together, these experiments identify FAK family activity as a critical effector downstream of MET involved in preserving CDK2 activity and clonogenic potential in cells exposed to CDK4/6i. They further suggest TP53-independent CDKN1A transcript accumulation as a candidate mechanism by which inhibition of MET/FAK promotes CDK4/6i-resistant CDK2-activation and cell cycle activity.
SKP2 is the critical common target engaged by MET and CDK4/6.
In addition to the increase in p21 CIP1 our earlier results showed a loss of SKP2 following combined CDK4/6 and MET-inhibition ( Fig. 5e-h ). SKP2 mediates the degradation of p21 CIP1 [37] and itself is targeted for degradation involving RB1 [15, 16] . Therefore, SKP2
loss may be the consequence of sustained RB1 activity, following from effective control of CDK2 activity through p21 CIP1 . And SKP2 loss may stabilise p21 CIP1 , synthesised from transcript that accumulates as a consequence of inhibition of the MET/FAK axis.
To test if this model explains how METis and CDK4/6is synergise, we used siRNA or inhibitors to ablate relevant components and assessed the effect of this on SKP2 loss and p21 CIP1 accumulation (Fig. 7) . Consistent with the model ablation of RB proteins abolished SKP2 loss and p21 CIP1 accumulation following combined MET and CDK4/6-inhibition ( Fig.   7a and 7b ). Also consistent with this model, PTK2 ablation, or pharmacological inhibition of FAK family activity using defactinib, were sufficient to trigger p21 CIP1 accumulation but insufficient to cause SKP2 loss, for which additional inhibition of CDK4/6 was required ( Fig.   7c and 7d ).
Unexpectedly, SKP2 loss ( Fig. 7e and 7f ), predicted to require MET-inhibition in order to yield upregulation of p21 CIP1 , yielded p21 CIP1 accumulation that was not further enhanced by MET-inhibition. This result indicates that p21 CIP1 transcript up-regulation caused by METinhibition may not be essential for p21 CIP1 accumulation, at least under conditions where SKP2 is absent at the outset, and could indicate that MET/FAK inhibition could have involvement in promoting SKP2 loss, independent from the degradation that it may enable by cooperating with CDK4/6-inhibition towards RB1-activation. Consistent with this prediction we found that MET-inhibition, in addition to increasing transcript levels for p21 CIP1 , suppressed transcript levels for SKP2, which like the increase in p21 CIP1 transcript was counteracted by constitutively active PTK2 (Fig. 7g ). Also consistent with this prediction we found that SKP2 loss enabled palbociclib to control CDK2-activation without additional MET-inhibition ( Supplementary Fig. 6 ).
Together these data support a mechanistic model (Fig. 7h ) in which SKP2 acts as a common target engaged by MET and CDK4/6 and proposes FAK-driven SKP2⎯and potentially p21 CIP1 transcript regulation⎯as mechanistic events through which the MET/FAK axis confers refractory response to CDK4/6-inhibition, and through which METinhibition synergises with CDK4/6-inhibition to deliver increased anticancer activity.
Discussion
Widespread recognition exists that CDK2-activation is associated with acquired resistance of cancer cells to CDK4/6-targeting cancer therapeutics [21] [22] [23] and also that CDK2 supports CDK4/6-independent proliferation during organismal development [20] . However, the molecular determinants that permit activation of CDK2 in these contexts have not been systematically sought. CDK4/6-selective inhibitors are now showing considerable promise in patients with estrogen receptor-positive breast cancer, yet there is clear need to identify functions that drive resistance in treatments involving these agents and that preclude their broader use in other cancer types. Here we report that activation of the MET/FAK signalling axis leads to CDK4/6-independent CDK2 activation, and constitutes a broadly applicable druggable means to improve the response of cancers to CDK4/6-targeted therapies.
MET is widely expressed in epithelial and endothelial cells, including cancers derived from these tissues, and may be activated in cancer cells through mutation. However, more frequently MET signalling is activated by the hepatocyte growth factor/ scatter factor, HGF, produced by adjacent mesenchymal tissues, including stromal components of cancers [38] [39] [40] .
We identified the MET/FAK axis based on a functional genetic screen using CDK2 activity as a mechanism-based endpoint. Apart from the MET/FAK axis, which we mechanistically explore in our work, the screen yielded other hits without known links to MET and/or FAK signalling, including ontology noted previously for synergistic interaction with catalytic inhibition of CDK4/6 such as RPS6KA6 and BRAF, inhibitors of which increase the response of cancer cells to CDK4/6-inhibition [2, 21, 41] . Unexpectedly, our screen indicates that TP53 status affects the spectrum of molecular functions required to support CDK4/6 independent CDK2-activation, with requirement of certain functions, including e.g.
RPS6KA6, confined to TP53 normal backgrounds. While further validation is required, these observations suggest that the TP53 status could determine efficacy of certain combinations.
In addition to MET, the screen identified FAK family kinases, that our subsequent work validates as a critical component by which MET elicits CDK4/6-independent CDK2-activation. Our experiments involving a constitutively-active form of the FAK family kinase PTK2 demonstrate that FAK activity is sufficient to elicit significant CDK4/6i tolerance. In the experimental models examined, MET scores as a key determinant responsible for FAK as a potentially powerful approach to improve the outcome for patients treated with CDK4/6-targeted therapies or to expand the current, approved indications through mechanismbased targeted combinations.
Methods
Cell culture, chemicals and antibodies: HCT116 TP53 -/-and isogenic HCT116 TP53 wt cells were provided by the Vogelstein laboratory (John Hopkins University, Baltimore, MD).
Other cell lines were acquired from the American Type Culture Collection (ATCC). HCT116-PSLD are described in [26] . Cells expressing CD2-PTK2 were constructed by lentiviral transduction using pLV-neo-CD2-FAK [50] . Inhibitors used were purchased from Selleck Chemicals. Antibodies and siRNAs used are summarized in supplementary materials. Research UK Life Fellow. The funders had no role in design of the study, the collection, analysis, and interpretation of the data the writing of the manuscript or the decision to submit the manuscript for publication. 
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MST1R (4) SI ≥ 0.25 0.10 < SI < 0.25 relating to loss of CDK2 activity in combination with CDK4/6-inhibiton using palbociclib, determined using GFP-PSLD localisation. Data are mean ±SD for n=3 independent repeats.
d-e Concentration-effect analysis depicting change in the fraction of cells with low CDK4/6 activity, assessed using automated microscopy analysis of cells immunostained for pRB1 S780 (d) or low CDK2 activity, assessed based on GFP-PSLD localisation (e) following individual or combined inhibition of CDK4/6, using palboclib, and MET, using crizotinib.
Data are mean ±SD for independent repeats. ****p≤ 0.0001, ns p> 0.05, 1-way ANOVA comparing effects across concentrations against vehicle or comparing palbociclib alone against palbociclib plus crizotinib (d) and comparing palbociclib alone or crizotinib alone against palbociclib plus crizotinib (e).
f CI value plot calculated from data in E. Fa= fraction affected. (Related to Supplementary Fig. 2 and Supplementary Fig. 3 ) This one h
